https://orcid.org/0000-0003-3817-6696
References
- Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366(16):1515–1525. doi:10.1056/NEJMra1103442
- Mirzoyev SA, Schrum AG, Davis MDP, et al. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Invest Dermatol. 2014;134(4):1141–1142. doi:10.1038/jid.2013.464
- Murad A, Maguire J, Bergfeld W. Drug-induced alopecia areata? Clin Exp Dermatol. 2021;46(2):363–366. doi:10.1111/ced.14381
- Martora F, Vastarella M, Fattore D, et al. Oral minoxidil for chemotherapy-induced alopecia. Skin Appendage Disord. 2022;8(6):508–510. doi:10.1159/000525463
- Zimmermann J, Buhl T, Müller M. Alopecia universalis following alemtuzumab treatment in multiple sclerosis: a barely recognized manifestation of secondary autoimmunity-report of a case and review of the literature. Front Neurol. 2017;8:569. doi:10.3389/fneur.2017.00569
- Chung J, Slaught CL, Simpson EL. Alopecia areata in 2 patients treated with dupilumab: new onset and worsening. JAAD Case Rep. 2019;5(8):643–645. doi:10.1016/j.jdcr.2019.03.019
- Yalici Armagan B, Atakan N. New onset alopecia areata during secukinumab therapy. Dermatol Ther. 2019;32(5):e13071. doi:10.1111/dth.13071
- Sun J, Xu W, Hua H, et al. Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor. Biomed Pharmacother. 2020;129:110410. doi:10.1016/j.biopha.2020.110410
- Hu Y, Zhang H, Li X, et al. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers. Expert Opin Investig Drugs. 2022;31(9):977–985. doi:10.1080/13543784.2021.1985464
- Mangkorntongsakul V, Thilagarajan C, Arianejad F, et al. Alopecia areata: a rare side effect of prazosin. Australas J Dermatol. 2021;62(3):443–445. doi:10.1111/ajd.13648
- Cantelli M, Martora F, Patruno C, et al. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022;35(4):e15346. doi:10.1111/dth.15346
- Martora F, Villani A, Ocampo‐Garza SS, et al. Alopecia universalis improvement following risankizumab in a psoriasis patient. J Eur Acad Dermatol Venereol. 2022;36(7):e543–e545. doi:10.1111/jdv.18017